KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Accumulated Expenses for 10 consecutive years, with $128.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses rose 27.98% to $128.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $128.9 million, a 27.98% increase, with the full-year FY2024 number at $128.9 million, up 27.98% from a year prior.
  • Accumulated Expenses was $128.9 million for Q4 2024 at Halozyme Therapeutics, up from $117.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $128.9 million in Q4 2024 to a low of $96.5 million in Q4 2022.
  • A 3-year average of $111.0 million and a median of $109.3 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: grew 4.31% in 2023, then increased 27.98% in 2024.
  • Halozyme Therapeutics' Accumulated Expenses stood at $96.5 million in 2022, then rose by 4.31% to $100.7 million in 2023, then rose by 27.98% to $128.9 million in 2024.
  • Per Business Quant, the three most recent readings for HALO's Accumulated Expenses are $128.9 million (Q4 2024), $117.9 million (Q2 2024), and $100.7 million (Q4 2023).